{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T20:17:39Z","timestamp":1791231459128,"version":"4.1.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,10,1]],"date-time":"2013-10-01T00:00:00Z","timestamp":1380585600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2014,9,5]],"date-time":"2014-09-05T00:00:00Z","timestamp":1409875200000},"content-version":"vor","delay-in-days":339,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"name":"Conselho Nacional de Desenvolvimento Cient\u00edfico e Tecnol\u00f3gico (CNPq)"},{"name":"Funda\u00e7\u00e3o de Amparo \u00e0 Pesquisa do Estado do Rio de Janeiro (FAPERJ)"},{"name":"FAPERJ\/PPSUS"},{"name":"Instituto Nacional de Ci\u00eancia e Tecnologia (INCT-para controle do c\u00e2ncer)"},{"name":"Programa de Oncobiologia (UFRJ\/Funda\u00e7\u00e3o do C\u00e2ncer)"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Leukemia Research"],"published-print":{"date-parts":[[2013,10]]},"DOI":"10.1016\/j.leukres.2013.06.014","type":"journal-article","created":{"date-parts":[[2013,7,25]],"date-time":"2013-07-25T13:46:52Z","timestamp":1374760012000},"page":"1350-1358","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells"],"prefix":"10.1016","volume":"37","author":[{"given":"Karina Lani","family":"Silva","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paloma Silva","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriela","family":"Nestal de Moraes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur","family":"Moellmann-Coelho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavia da Cunha","family":"Vasconcelos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raquel Ciuvalschi","family":"Maia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"11","key":"10.1016\/j.leukres.2013.06.014_bib0005","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1056\/NEJMoa022457","article-title":"Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia","volume":"348","author":"O\u2019Brien","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.leukres.2013.06.014_bib0010","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1200\/JCO.2010.31.3619","article-title":"Front-line and salvage therapies with tyrosine kinase inhibitors and other treatments in chronic myeloid leukemia","volume":"29","author":"Cortes","year":"2011","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.leukres.2013.06.014_bib0015","doi-asserted-by":"crossref","first-page":"e71","DOI":"10.3747\/co.v18i2.391","article-title":"Monitoring response and resistance to treatment in chronic myeloid leukemia","volume":"18","author":"Assouline","year":"2011","journal-title":"Curr Oncol"},{"key":"10.1016\/j.leukres.2013.06.014_bib0020","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/671702","article-title":"The interface between BCR-ABL-dependent and \u2013 independent: resistance signaling pathways in chronic myeloid leukemia","author":"Nestal de Moraes","year":"2012","journal-title":"Leuk Res Treatment"},{"issue":"2","key":"10.1016\/j.leukres.2013.06.014_bib0025","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/nrd3627","article-title":"Targeting IAP proteins for therapeutic intervention in cancer","volume":"11","author":"Fulda","year":"2012","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.leukres.2013.06.014_bib0030","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.canlet.2004.10.034","article-title":"Survivin expression in chronic myeloid leukemia","volume":"225","author":"Conte","year":"2005","journal-title":"Cancer Lett"},{"issue":"5","key":"10.1016\/j.leukres.2013.06.014_bib0035","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1080\/10428190500052131","article-title":"Survivin expression in the progression of chronic myeloid leukemia: a sequential study in 16 patients","volume":"46","author":"Hern\u00e1ndez-Boluda","year":"2005","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.leukres.2013.06.014_bib0040","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.clim.2011.01.010","article-title":"Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses","volume":"139","author":"Speletas","year":"2011","journal-title":"Clin Immunol"},{"issue":"6","key":"10.1016\/j.leukres.2013.06.014_bib0045","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1182\/blood.V96.6.2246","article-title":"CGP57148B (STI-571) induces differentiation and apoptosis and sensitizes Bcr-Abl-positive human leukemia cells to apoptosis due to antileukemic drugs","volume":"96","author":"Fang","year":"2000","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.leukres.2013.06.014_bib0050","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1179\/joc.2006.18.1.98","article-title":"Chemosensitization effects of XIAP downregulation in K562 leukemia cells","volume":"18","author":"Lima","year":"2006","journal-title":"J Chemother"},{"issue":"5","key":"10.1016\/j.leukres.2013.06.014_bib0055","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.exphem.2012.01.004","article-title":"ABT-737 increases tyrosine kinase inhibitor-induced apoptosis in chronic myeloid leukemia cells through XIAP downregulation and sensitizes CD34(+) CD38(\u2212) population to imatinib","volume":"40","author":"Airiau","year":"2012","journal-title":"Exp Hematol"},{"issue":"11","key":"10.1016\/j.leukres.2013.06.014_bib0060","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1002\/ajh.20656","article-title":"IAP family protein expression correlates with poor outcome of multiple myeloma patients in association with chemotherapy-induced overexpression of multidrug resistance genes","volume":"81","author":"Nakagawa","year":"2006","journal-title":"Am J Hematol"},{"issue":"2","key":"10.1016\/j.leukres.2013.06.014_bib0065","first-page":"471","article-title":"Survivin and P-glycoprotein are associated and highly expressed in late phase chronic myeloid leukemia","volume":"26","author":"Reis","year":"2011","journal-title":"Oncol Rep"},{"issue":"4","key":"10.1016\/j.leukres.2013.06.014_bib0070","first-page":"925","article-title":"P-glycoprotein and survivin simultaneously regulate vincristine-induced apoptosis in chronic myeloid leukemia cells","volume":"39","author":"Souza","year":"2011","journal-title":"Int J Oncol"},{"key":"10.1016\/j.leukres.2013.06.014_bib0075","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"key":"10.1016\/j.leukres.2013.06.014_bib0080","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1590\/S0001-37652001000100007","article-title":"Multidrug resistance in tumour cells: characterization of the multidrug resistant cell line K562-Lucena 1","volume":"73","author":"Rumjanek","year":"2001","journal-title":"An Acad Bras Cienc"},{"issue":"3","key":"10.1016\/j.leukres.2013.06.014_bib0085","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0145-2126(02)00094-2","article-title":"CPT-11-induced cell death in leukemic cells is not affected by the MDR phenotype","volume":"27","author":"Silva","year":"2003","journal-title":"Leuk Res"},{"key":"10.1016\/j.leukres.2013.06.014_bib0090","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s10495-006-3560-5","article-title":"Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukaemia","volume":"11","author":"Silva","year":"2006","journal-title":"Apoptosis"},{"issue":"3","key":"10.1016\/j.leukres.2013.06.014_bib0095","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/cyto.b.20580","article-title":"Variation of MDR proteins expression and activity levels according to clinical status and evolution of CML patients","volume":"80","author":"Vasconcelos","year":"2011","journal-title":"Cytometry B Clin Cytom"},{"issue":"2","key":"10.1016\/j.leukres.2013.06.014_bib0100","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ab.2011.04.032","article-title":"Immunodetection of caspase-3 by Western blot using glutaraldehyde","volume":"415","author":"Nestal de Moraes","year":"2011","journal-title":"Anal Biochem"},{"key":"10.1016\/j.leukres.2013.06.014_bib0105","doi-asserted-by":"crossref","DOI":"10.1002\/cncr.27568","article-title":"Reverse phase protein array profiling reveals distinct proteomic signatures associated with chronic myeloid leukemia progression and with chronic phase in the CD34-positive compartment","author":"Quint\u00e1s-Cardama","year":"2012","journal-title":"Cancer"},{"issue":"12","key":"10.1016\/j.leukres.2013.06.014_bib0110","doi-asserted-by":"crossref","first-page":"4179","DOI":"10.1182\/blood-2003-03-0960","article-title":"Caspase-independent cell death in AML: caspase inhibition in vitro with pan-caspase inhibitors or in vivo by XIAP or Survivin does not affect cell survival or prognosis","volume":"102","author":"Carter","year":"2003","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.leukres.2013.06.014_bib0115","first-page":"2468","article-title":"Expression of X-linked inhibitor of apoptosis as a novel prognostic marker in radically resected non-small cell lung cancer patients","volume":"7","author":"Ferreira","year":"2001","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.leukres.2013.06.014_bib0120","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/1746-1596-6-49","article-title":"X-linked inhibitor of apoptosis positive nuclear labeling: a new independent prognostic biomarker of breast invasive ductal carcinoma","volume":"6","author":"Zhang","year":"2011","journal-title":"Diagn Pathol"},{"issue":"3","key":"10.1016\/j.leukres.2013.06.014_bib0125","doi-asserted-by":"crossref","first-page":"e31601","DOI":"10.1371\/journal.pone.0031601","article-title":"XIAP is a predictor of cisplatin-based chemotherapy response and prognosis for patients with advanced head and neck cancer","volume":"7","author":"Yang","year":"2012","journal-title":"PLoS ONE"},{"issue":"12","key":"10.1016\/j.leukres.2013.06.014_bib0130","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/sj.bjc.6605704","article-title":"Elevated XIAP expression alone does not confer chemoresistance","volume":"102","author":"Seeger","year":"2010","journal-title":"Br J Cancer"},{"issue":"12","key":"10.1016\/j.leukres.2013.06.014_bib0135","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1248\/bpb.30.2279","article-title":"The effect of survivin on multidrug resistance mediated by P-glycoprotein in MCF-7 and its adriamycin resistant cells","volume":"30","author":"Liu","year":"2007","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"10.1016\/j.leukres.2013.06.014_bib0140","first-page":"133","article-title":"Expression of the IAPs in multidrug resistant tumor cells","volume":"11","author":"Notarbartolo","year":"2004","journal-title":"Oncol Rep"},{"issue":"5","key":"10.1016\/j.leukres.2013.06.014_bib0145","first-page":"1469","article-title":"Survivin transcription is associated with P-glycoprotein\/MDR1 overexpression in the multidrug resistance of MCF-7 breast cancer cells","volume":"23","author":"Liu","year":"2010","journal-title":"Oncol Rep"},{"issue":"12","key":"10.1016\/j.leukres.2013.06.014_bib0150","doi-asserted-by":"crossref","first-page":"7024","DOI":"10.1073\/pnas.95.12.7024","article-title":"The drug efflux protein, P-glycoprotein, additionally protects drug-resistant tumor cells from multiple forms of caspase-dependent apoptosis","volume":"95","author":"Smyth","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"3","key":"10.1016\/j.leukres.2013.06.014_bib0155","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1182\/blood.V93.3.1075","article-title":"P-glycoprotein protects leukemia cells against caspase-dependent, but not caspase-independent, cell death","volume":"93","author":"Johnstone","year":"1999","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.leukres.2013.06.014_bib0160","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1038\/sj.leu.2403257","article-title":"P-glycoprotein-mediated drug efflux is a resistance mechanism of chronic myelogenous leukemia cells to treatment with imatinib mesylate","volume":"18","author":"Illmer","year":"2004","journal-title":"Leukemia"},{"issue":"8","key":"10.1016\/j.leukres.2013.06.014_bib0165","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1124\/dmd.109.031302","article-title":"Comparison of ATP-binding cassette transporter interactions with the tyrosine kinase inhibitors imatinib, nilotinib, and dasatinib","volume":"38","author":"Dohse","year":"2010","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"10.1016\/j.leukres.2013.06.014_bib0170","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.leukres.2008.09.024","article-title":"Imatinib resistance in multidrug-resistant K562 human leukemic cells","volume":"33","author":"Assef","year":"2009","journal-title":"Leuk Res"},{"issue":"1","key":"10.1016\/j.leukres.2013.06.014_bib0175","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.cancergencyto.2005.01.015","article-title":"Quantitative molecular monitoring of BCR-ABL and MDR1 transcripts in patients with chronic myeloid leukemia during imatinib treatment","volume":"162","author":"Galimberti","year":"2005","journal-title":"Cancer Genet Cytogenet"},{"issue":"1","key":"10.1016\/j.leukres.2013.06.014_bib0180","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1134\/S0006297908010045","article-title":"Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib","volume":"73","author":"Stromskaya","year":"2008","journal-title":"Biochemistry (Mosc)"},{"issue":"1","key":"10.1016\/j.leukres.2013.06.014_bib0185","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/1477-5956-10-23","article-title":"A comparative proteomic study identified LRPPRC and MCM7 as putative actors in imatinib mesylate cross-resistance in Lucena cell line","volume":"10","author":"Correa","year":"2012","journal-title":"Proteome Sci"},{"issue":"6","key":"10.1016\/j.leukres.2013.06.014_bib0190","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1111\/j.1349-7006.2003.tb01482.x","article-title":"Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells","volume":"94","author":"Mukai","year":"2003","journal-title":"Cancer Sci"},{"issue":"2","key":"10.1016\/j.leukres.2013.06.014_bib0195","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1179\/102453311X12940641877803","article-title":"Simultaneous targeting of P-gp and XIAP with siRNAs increases sensitivity of P-gp overexpressing CML cells to imatinib","volume":"16","author":"Seca","year":"2011","journal-title":"Hematology"},{"issue":"10","key":"10.1016\/j.leukres.2013.06.014_bib0200","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.3109\/10428194.2011.584005","article-title":"Development of imatinib and dasatinib resistance: dynamics of expression of drug transporters ABCB1, ABCC1, ABCG2, MVP, and SLC22A1","volume":"52","author":"Gromicho","year":"2011","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"10.1016\/j.leukres.2013.06.014_bib0205","doi-asserted-by":"crossref","first-page":"110","DOI":"10.5732\/cjc.011.10327","article-title":"Overexpression of P-glycoprotein induces acquired resistance to imatinib in chronic myelogenous leukemia cells","volume":"31","author":"Peng","year":"2012","journal-title":"Chin J Cancer"},{"issue":"2","key":"10.1016\/j.leukres.2013.06.014_bib0210","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1182\/blood.V99.2.664","article-title":"Effects of the Bcr\/abl kinase inhibitors STI571 and adaphostin (NSC 680410) on chronic myelogenous leukemia cells in vitro","volume":"99","author":"Mow","year":"2002","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.leukres.2013.06.014_bib0215","first-page":"969","article-title":"Overexpression of Survivin and XIAP in MDR cancer cells unrelated to P-glycoprotein","volume":"17","author":"Shi","year":"2007","journal-title":"Oncol Rep"},{"issue":"17","key":"10.1016\/j.leukres.2013.06.014_bib0220","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1038\/sj.onc.1205353","article-title":"Human survivin is negatively regulated by wild-type p53 and participates in p53-dependent apoptotic pathway","volume":"21","author":"Mirza","year":"2002","journal-title":"Oncogene"},{"issue":"5043","key":"10.1016\/j.leukres.2013.06.014_bib0225","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1126\/science.1346476","article-title":"Modulation of activity of the promoter of the human MDR1 gene by Ras and p53","volume":"255","author":"Chin","year":"1992","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.leukres.2013.06.014_bib0230","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1084\/jem.188.1.211","article-title":"Nuclear factor (NF)-kappaB-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha-induced apoptosis","volume":"188","author":"Stehlik","year":"1998","journal-title":"J Exp Med"}],"container-title":["Leukemia Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613002002?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0145212613002002?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T00:58:30Z","timestamp":1758934710000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0145212613002002"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,10]]},"references-count":46,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,10]]}},"alternative-id":["S0145212613002002"],"URL":"https:\/\/doi.org\/10.1016\/j.leukres.2013.06.014","relation":{},"ISSN":["0145-2126"],"issn-type":[{"value":"0145-2126","type":"print"}],"subject":[],"published":{"date-parts":[[2013,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"XIAP and P-glycoprotein co-expression is related to imatinib resistance in chronic myeloid leukemia cells","name":"articletitle","label":"Article Title"},{"value":"Leukemia Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.leukres.2013.06.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}